Al-Shahrestani Fahd, Al-Khafaf Ahmed Ehsan, Asheer Zain, Jelicic Jelena, Chanchiri Iman, Blocher Catharina E, Sørensen Anne Kathrine Aalling, Pedersen Lars Møller, Gjerdrum Lise Mette Rahbek, Heegaard Steffen, Homøe Preben
Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Køge, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Eur Arch Otorhinolaryngol. 2025 Apr;282(4):2021-2031. doi: 10.1007/s00405-024-09008-x. Epub 2024 Oct 8.
This study explores the epidemiology, incidence, and survival outcomes associated with lymphomas of the submandibular gland (SMG) and examines the influence of autoimmune diseases on these parameters.
This retrospective nationwide cohort study analysed data from patients diagnosed with SMG lymphomas in Denmark between 2000 and 2020. Information was extracted from medical records, the National Pathology Register, and the Danish Lymphoma Database. Survival analyses were conducted using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models, focusing on lymphoma subtypes and autoimmune diseases.
The cohort consisted of 101 patients with a lymphoma diagnosis and involvement of the SMG. Large B-cell lymphoma (LBCL) was diagnosed in 33 cases (32.7%), follicular lymphoma (FL) in 29 cases (28.7%), extranodal marginal zone lymphoma (EMZL) in 27 cases (26.7%), and 12 cases (11.9%) with other subtypes. EMZL had a significantly longer overall survival (OS) compared to other subtypes, with a median OS of 12.4 years (95% CI 11.2-12.4) vs. 8.4 years (95% CI 6.0-12.2). EMZL and FL showed favourable 5-year OS rates of 95% and 89%, respectively. LBCL had a 5-year OS rate of 65%. Age over 60 significantly negatively impacted OS. Traditional poor prognostic indicators did not significantly affect OS. A notable association between EMZL and autoimmune diseases was observed, particularly with Sjögren's syndrome, indicated by an increased relative risk of 2.67 (CI 95% 0.45-16.01).
Lymphomas of the SMG are rare and have ambiguous clinical presentations. This study provides novel epidemiological, clinical, and prognostic information.
本研究探讨下颌下腺淋巴瘤(SMG)的流行病学、发病率及生存结局,并研究自身免疫性疾病对这些参数的影响。
这项全国性回顾性队列研究分析了2000年至2020年间丹麦诊断为SMG淋巴瘤患者的数据。信息从医疗记录、国家病理登记册和丹麦淋巴瘤数据库中提取。使用Kaplan-Meier曲线、对数秩检验和Cox比例风险模型进行生存分析,重点关注淋巴瘤亚型和自身免疫性疾病。
该队列包括101例诊断为淋巴瘤且累及SMG的患者。33例(32.7%)诊断为大B细胞淋巴瘤(LBCL),29例(28.7%)为滤泡性淋巴瘤(FL),27例(26.7%)为结外边缘区淋巴瘤(EMZL),12例(11.9%)为其他亚型。与其他亚型相比,EMZL的总生存期(OS)显著更长,中位OS为12.4年(95%CI 11.2-12.4),而其他亚型为8.4年(95%CI 6.0-12.2)。EMZL和FL的5年OS率分别为95%和89%,表现良好。LBCL的5年OS率为65%。60岁以上显著对OS产生负面影响。传统的不良预后指标对OS没有显著影响。观察到EMZL与自身免疫性疾病之间存在显著关联,尤其是与干燥综合征,相对风险增加2.67(95%CI 0.45-16.01)。
SMG淋巴瘤罕见,临床表现不明确。本研究提供了新的流行病学、临床和预后信息。